Risk/ benefit af den kombinerede anvendelse af interferon alfa- 2b og ribavirin bør derfor vurderes hos små børn før initiering af behandling.
In addition, preclicinal juvenile toxicity results have demonstrated a minor, dose-related decrease in overall growth in neonatal rats dosed with ribavirin (see section 5.3).